<DOC>
	<DOCNO>NCT03020628</DOCNO>
	<brief_summary>This study multi-center , randomize , double-blind Phase III Clinical trial . The purpose study assess immunogenicity safety quadrivalent cell culture-derived influenza vaccine compare trivalent cell culture-derived influenza vaccine child age 6~35 month .</brief_summary>
	<brief_title>Immunogenicity Safety Quadrivalent Influenza Vaccine Children Aged 6~35 Months</brief_title>
	<detailed_description>Subjects randomly assign 2:1 ratio NBP607-QIV 0.5mL versus NBP607-TIV 0.25mL . To assess immunogenicity , antibody level evaluate hemagglutination inhibition ( HI ) assay serum obtain pre-vaccination 28 day post-vaccination . To assess safety , solicited adverse event 7 day post-vaccination unsolicited adverse event 28 day post-vaccination assess report . The serious adverse event collect 6 month post-vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children age 6 month 35 month Those bear normal pregnancy period ( 37 week ) age 6 month &lt; 1 year Those whose legally acceptable representative give write consent participate study comply study requirement . Subjects immune deficiency disorder malignant cancer . History hypersensitivity follow administration vaccine GuillainBarre syndrome . Thrombocytopenia bleed disorder contraindicate intramuscular vaccination . Subjects experience fever within 72 hour vaccination febrile disease ( exceed 38.0â„ƒ ) screening day . Subjects receive immunosuppressant immunemodifying drug within 3 month screen . Subjects receive blood product immunoglobulin within 3 month screen . Subjects receive influenza vaccination within 6 month prior screen . Subjects receive vaccination within month screening , another vaccination schedule within month study vaccination . Subjects receive investigational product within 4 week prior study vaccination . Subjects clinically significant chronic disease . Any condition , opinion Investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Influenza Vaccines</keyword>
	<keyword>Vaccines , Inactivated</keyword>
	<keyword>Cell Culture-Derived</keyword>
</DOC>